However, the local treatment with selective COX-2 inhibitors in glaucoma could provide an innovative therapeutic intervention and could open up a complete new field of indication for existing COX-2 inhibitors avoiding these dangerous side effects. This evidence concerns the gene PTGER2 and glaucoma.